Stockscreener 앱 받기
0.3899
7.04%
-0.015
Sensei Biotherapeutics Inc 주식(SNSE)의 최신 뉴스
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating - Marketscreener.com
Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year - TipRanks
Sensei stock holds Buy rating, $4 target from H.C. Wainwright - Investing.com
Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026 - MarketScreener
Sensei Biotherapeutics, Inc. SEC 10-K Report - TradingView
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewswire
Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors - Stock Titan
Sensei Biotherapeutics announces initial results from solnerstotug trial portion - TipRanks
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors - Marketscreener.com
Sensei Biotherapeutics : Company Presentation March 2025 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewswire
Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed - Stock Titan
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest - Defense World
Sensei Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN
A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Biotech Spotlight: Sensei Bio Takes Center Stage at Major Healthcare Conference - StockTitan
Sensei Biotherapeutics, Inc. Appoints Robert Pierce as Chief Scientific Officer; Opens its Boston Office - Marketscreener.com
Sensei Biotherapeutics Inc Shares Rise 25.49% From The Lows – But Will They Continue? - Marketing Sentinel
Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports
Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright - Defense World
Sensei Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones - The Manila Times
Sensei Bio's Cancer Drug Shows Promise in Phase 1/2 Trial, Enrolls 45 Patients for VISTA Study - StockTitan
Sensei Biotherapeutics faces Nasdaq delisting risk - Investing.com
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - GlobeNewswire
Sensei Biotherapeutics Q3 2024 Results and Strategic Moves - TipRanks
0.63%
자본화:
|
볼륨(24시간):